BIOTECH ASSISTANT / FIELD NOTES

Updated abacavir PopPK model extends pediatric analysis to neonates and young infants

Academic source · Antimicrobial Agents and Chemotherapy

Source published: 2026-11-03 · Event / reporting date: 2026-11-03

Site published: 2026-11-08 · Updated: 2026-11-08

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

Based on the original abstract, researchers extended an abacavir population pharmacokinetic model using IMPAACT 2019 and PETITE data alongside historical pediatric studies. The final model included maturation of oral clearance and age-dependent absorption, capturing higher exposure in neonates and young infants with immature metabolism. The work supports dosing research rather than a new regulatory approval.

Why this paper is included

Analysis: Explicit maturation modeling may improve pediatric development plans and reduce reliance on body-weight extrapolation alone when evaluating neonatal exposure.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Clinical Pharmacology & Model-Informed Development

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Pharmaron Quotient Sciences Crystal Bio Solutions Frontage Laboratories Altasciences

Explore field companies →Explore literature →

Related updates

2026-11-07Scientific Reports

Methotrexate PBPK model examines pediatric extrapolation, drug interactions, and renal impairment

A Scientific Reports study developed a whole-body model of methotrexate and its metabolite using adult and pediatric pharmacokinetic profiles. Predicted exposure measures were generally within twofold of observed values. Simulations examined five interacting drugs and indicated increased exposure with renal impairment at high doses. These are model-based assessments, not prospective evidence that a dosing regimen improves clinical outcomes.

Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-07Arrowhead Pharmaceuticals

ARO-DIMER-PA shows dual lipid lowering in early human study, with dose-related safety findings

Arrowhead reported Phase 1/2a interim data involving 21 ARO-DIMER-PA recipients and 10 placebo recipients. Across dose cohorts, mean LDL-C fell 26%–65% and median triglycerides fell 56%–78% from baseline; these were not placebo-adjusted effects. Injection-site erythema occurred in 20 treated participants, and one participant receiving 400 mg experienced Grade 3 syncope. Cardiovascular outcome benefit remains unestablished.

Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-07Cleveland Clinic

Lp(a)HORIZON reports neutral cardiovascular outcomes despite substantial pelacarsen biomarker reduction

Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.

Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed Development Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗